louisakewell, Author at European Medical Journal - Page 45 of 153

Continue
2 Mins
6th March 2017

Pfizer Selects Turner & Townsend for Expansion of Its Clinical Research Unit in Belgium

Turner & Townsend, the global professional services consultancy, has successfully delivered the first of two fit outs on behalf of Pfizer Clinical…
8 Mins
6th March 2017

New Results from Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis

Orlando, Florida, 3 March, 2017 ― Janssen Research & Development, LLC (Janssen) announced today new findings from two pivotal Phase 3 studies reporting…
3 Mins
3rd March 2017

Clinical and Preclinical Data on Monalizumab to Be Presented at AACR Annual Meeting 2017

Marseille, France, March 2, 2017 – Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today announces that data on monalizumab will be…
2 Mins
2nd March 2017

Introducing the European Medical Journal 2.1

United Kingdom, March 2, 2017: A warm welcome to the year’s first issue of the flagship eJournal, the European Medical Journal. Contained within is a…
10 Mins
23rd February 2017

Positive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma

GlaxoSmithKline plc and Innoviva, Inc. today announced positive headline results from a non-inferiority lung function study
4 Mins
23rd February 2017

Philips Reinforces Leadership in Image-Guided Therapy Solutions with Global Launch of next Generation Azurion Platform

Amsterdam, the Netherlands, February 22, 2017 – Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the global launch of…
5 Mins
17th February 2017

Janssen Presents Newly-Published Data on the Use of ZYTIGA® (Abiraterone Acetate) Plus Prednisone in the Real-World, Outside the Clinical Trial Setting

Beerse, Belgium, February 17, 2017 – Janssen-Cilag International NV today announced the publication of data revealing radiographic progression-free…
5 Mins
17th February 2017

New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn’s Disease

Barcelona, Spain, February 17, 2017 – Janssen-Cilag International NV (“Janssen”) announced today new two-year data from the ongoing IM-UNITI long-term…
3 Mins
16th February 2017

Polyganics’ “STOP NEUROMA” Study Interim Data Shows Reduction in Pain

Groningen, The Netherlands, February 16, 2017 – Polyganics, a privately held medical technology company, announced today that interim results show a…
5 Mins
10th February 2017

BIAL and Neurocrine Announce Exclusive North American Licensing Agreement for Opicapone

Porto, Portugal and San Diego, California, February 10, 2017 – BIAL and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that they have…